LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Tick Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Newsletter Volume 3 Issue 09 LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Home LymeNet Newsletter Library

Volume: 3
Issue: 09
Date: 14-Jun-95


Table of Contents:

I.    LYMENET: Vancouver LD Conference Notes - Part 1
II.   About The LymeNet Newsletter


Newsletter:

***********************************************************************
*                  The National Lyme Disease Network                  *
*                         LymeNet Newsletter                          *
***********************************************************************


IDX#                Volume 3 - Number 09 - 6/14/95
IDX#                            INDEX
IDX#
IDX#  I.    LYMENET: Vancouver LD Conference Notes - Part 1
IDX#  II.   About The LymeNet Newsletter
IDX#



I.    LYMENET: Vancouver LD Conference Notes - Part 1
-----------------------------------------------------
Sender: Lloyd E. Miller, DVM <LloydEM@aol.com>


Notes from the VIII Annual Lyme Disease Foundation Scientific
Conference on Lyme Borreliosis and other Spirochetal and Tick-Borne
Diseases - Held April 28-29 1995 -- at Vancouver, British Columbia,
Canada.


Part 1

Prepared by Lloyd E. Miller, DVM

Every effort has been made to be accurate.  Please report any
additions or corrections.  Always confirm drug doses and names of
medications with another source before using.



EPIZOOLOGY, EPIDEMIOLOGY

1. Update on the epizootiology of Borrelia burgdorferi in southeastern
U.S. - J. Oliver, Ph.D.


Documented the finding Bb infected ticks (Ixodes scapularis and Ixodes
dentatus), on cotton rats and wood rats in of southeastern states
(Missouri, So. Carolina, Georgia, and Florida).  In some areas
Infectivity rates of rodents can be as high as 75%.  Showed that the
populations of Bb and Ix. Scapularis have more genetic variability in
the south than in the north.  Made the case that this implies the
populations with the most variability are the oldest populations and
that instead of Bb and Ixodes scapularis spreading from north to south
the opposite may have occurred.  He pointed out that in LD a lot of
assumptions are made - forgetting that exceptions do occur.


2. Ecology of Lyme disease in Northeastern United States - J.F.
Anderson, Ph.D.


Ixodes scapularis has been recorded feeding on 120 species of animals
(birds, mammals, lizards).  Infectivity rates in ticks in northeast
varies by locality from 12 to 100% as compared to 1-3% in the
southeast and west.  Part of reason may be that in the northeast
ticks feed primarily on mammals where in the southeast and west ticks
also feed on lizards which can break the Infectivity cycle.


3. Isolation of B. burgdorferi in British Columbia during 1992-1994 -
S. N. Banerjee, Ph.D.


Showed evidence of the endemic status of British Columbia through the
isolation of Bb from Ixodes angustus and Ixodes pacificus ticks.


4. Lyme disease in British Columbia - P. Daly, M.D

Lyme disease is a reportable disease in British Columbia since June
1994.  As in the USA the Canadian surveillance definition of Lyme
disease is quite restricted.


5. Lyme Disease cases acquired in British Columbia 1992-1994 - R. Gill

Reported the acquisition of Lyme disease within the boundaries of
British Columbia in 11 patients (out of 43 known cases), further
demonstrating the endemic status of British Columbia.  Only two of
the 11 had an EM rash.


6. Surveillance for Tick-borne Relapsing Fever in Texas Caves -
J. Rawlings MPH


Evidence was presented that Tick-borne Relapsing Fever can be acquired
in caves.  The disease is also transmitted by tick bite (Ornithodorus
turicata) and is caused by Borrelia turicatae.


VACCINE PROGRESS

7. Induction of Lyme arthritis and role of Borrelia burgdorferi
specific T-lymphocytes - R. Schell, Ph.D.


This presentation was a continuation of research reported at this same
conference last year in which it was reported that hamsters challenged
with homologous stains of Bb developed severe arthritis post
vaccination and prior to the development of immunity.  It was also
reported that when the protective titer waned arthritis would also
develop on challenge.  This report shows that Bb specific
T-lymphocytes were responsible for the development of the arthritis.
The importance of this is related to the development of safe and
effective vaccination and in the development of medications that may
prevent or treat the arthritis caused by Bb.


8. Efficacy of recombinant OspA formulations in Rhesus monkey  - M.
Philip, Ph.D


* Monkeys were vaccinated with 3 doses intramuscularly at four week
 intervals and then challenged by bite of nymphal Ixodes scapularis 5
 weeks post vaccination.
* One of 130 ticks that fed on vaccinates was found to contain Bb
 following feeding. From control monkeys 48 of 50 were still
 infected.
* Control animals developed significant response to Bb antigens on
 western blot at 4 and 40 weeks post challenge. Bb was found in the
 skin by PCR during the 4 weeks post challenge.  Inflammation and
 positive PCR was observed in urinary tract (2/4), heart (3/4),
 joints (1/4) and nerves (4/4), lung (4/4).
* None of the vaccinates reacted to any Bb antigens on western blot
 except the OspA of the vaccine.  Bb was not found in the skin by
 PCR during the 4 weeks post challenge.  Inflammation and positive
 PCR were not observed in the urinary tract or joints.  However,  
 *very significantly*, inflammation and positive PCR was observed
 in nerves (2/6), heart (2/6) and lung (5/6).
* The abstract states that: "The difference in the tick infection rate

 between ticks that fed on vaccinated animals, the lack of
 seroconversion in the vaccinated animals and the absence of
 spirochetal DNA in the skin of the vaccinated animals in the weeks
 following the challenge, indicate that the vaccinated monkeys were
 protected against tick challenge,"
* Note the affinity of Bb for the nerves, heart and lung.
* Were the monkeys really protected against *infection*?  Note not all
 monkeys were examined so it will be possible in the future to
 determine whether the Bb found in the vaccinates were transiently
 infecting or whether the vaccine prevented all but a small number
 of Bb to infect (a number low enough to not cause immune response).
 This will be very important to determine for unless the vaccine can
 prevent infection it may not prevent chronic infection and possible
 long term  disease consequences.  The authors are continuing their
 study and hopefully will answer this question.


[ Comment - Were the monkeys really protected against *infection*?
 Note not all vaccinated monkeys have been examined so hopefully it
 will be possible in the future to determine whether the Bb found
 in the vaccinates were transiently infecting or whether the vaccine
 prevented all but a small number of Bb to infect (a number low
 enough to not stimulate immune response).  This will be very
 important to determine for unless the vaccine can prevent infection
 it may not prevent chronic infection and possible long term disease
 consequences.  The authors are continuing their study and hopefully
 will answer this question.  The reason(s) for this finding must be
 addressed before vaccination programs for humans are developed. ]


9. Update on recombinant Lyme disease vaccine development - A. Barbour,
M.D.


Several of the Osp proteins are candidates for incorporation in a
vaccine OspA,B and C are known to produce immune protection in
animals.  OspD is found in some Bb that do not express OspA or B.
OspE and F are described but it is not known if they can produce
protective immunity.  It is now reported that Bb expresses OspA when
in ticks but OspA is rarely found when Bb infects humans and animals
(mouse, hamster, monkey and dog).  Some Bb isolates process the OspA
gene but don't express OspA.  Once Bb is transmitted to mammals OspA
production declines.  Therefore, if an OspA based vaccine is going to
work Anti-OspA antibody must be present at the site of tick bite at
the time the bite occurs.  *This means the vaccine will not help
anyone who already has been infected*.  Safety studies on the OspA
vaccines have shown them to be safe.  There are no reactions other
than what is seen with any other vaccine.  Studies have shown that
the vaccine produces an immune response resulting in the production
of anti-OspA antibodies.


[ Comment - I was disappointed to learn that endpoint of the
 vaccination trials currently in progress as I understand them, is
 observing whether or not EM develops in vaccinated individuals.
 Many of the attendees I spoke to thought this was an inadequate
 test of efficacy.  We know that EM is observed in only
 approximately 50% of those infected.  There is no study, as far as
 I could ascertain, that attempts to determine whether prevention of
 infection occurs following vaccination.  (If I'm wrong I hope
 someone out there will reassure us).  It should be noted, based on
 the monkey study reported herein, that total prevention of
 infection by vaccination must be determined for it may do no good
 to vaccinate to prevent the early development of Lyme disease
 symptoms only to have later symptoms develop.  As noted also herein,
 treatment of the early symptoms is far more successful than the
 treatment of later stage symptoms.  Vaccination in this case will
 give a false sense of security and may result in even more cases of

 chronic debilitating disease!  Given the ability of Bb to persist,
 total prevention of infection MUST be the goal of vaccination. ]


PATHOGENESIS OF DISSEMINATION

10. Antigenic variation of Borrelia burgdorferi sensu lato:
implications for pathogenesis, diagnosis and prophylaxis - B.
Wilske, MD


This work was done in Europe using Ixodes ricinus ticks but it was
stated that the information held true for the American ticks too.
Apparently Bb OspA is regularly expressed in ticks but once Bb is
transmitted to humans there is strong expression of OspC and low
expression of OspA.  They identified 7 types of OspA and 13 Types of
OspC.  They were able to show that in European patients disease
expression was significantly associated with OspA type expressed by
Bb isolates from the patient.  For instance Type 2 was associated
predominately with skin disease.  It is therefore predicted that
antigenic variation does have influence on the expression of disease.
Significance of these findings regarding diagnostic testing; if the
test is only looking for antibodies to OspA and not OspC then a false
negative test might result.  Antibodies against OspC will not protect
against OspA and vise versa thus a vaccine based only one may not
provide the required level of protection.


11. Virulent Borrelia burgdorferi specifically attach to, activate,
and kill TIB-215 Human B-Lymphocytes - D. Dorward, Ph.D.


Experiments were described showing that when Bb were incubated with
B-lymphocytes 50% of the cells were lysed.  The amount of lysing was
dose dependent and required live spirochetes.  A video was shown
demonstrating the entry of Bb into lymphocytes and the rupture of a
lymphocyte.  This type of interaction may play a roll in colonization
and persistence of Bb in mammals.


12. The Borrelia turicatea-mouse model of Lyme disease - A.
Barbour, M.D.


Using Borrelia turicatea which infects the peripheral and CNS of mice
it was determined that ONLY certain serotypes exhibit neurotropism.
Serotype A infects the brain; serotype B doesn't.  Serotype B causes
a severe polyarthritis; Serotype A causes only a mild arthritis.  The
only difference identified between Serotypes A and B is an outer
membrane protein that is homologous to OspC proteins of Bb.  This
finding suggests that disease manifestations of borrelial (including
LD) infections are at least in part determined by features of the
infecting organisms.  In this model ceftriaxone eliminated Borrelia
turicatea 100% from the brain; vancomycin did not.  


INNOVATIVE BIOLOGY

13. Further evidence for a spirochetal etiology of Alzheimer's
disease - J. Miklossy, M.D.


Information was presented reporting on the finding of spirochetes by
dark field microscopy in the blood, CSF and brain tissue of
Alzheimer's disease cases (14 of 14 cases).  Spirochetes were
cultured from 3 of 4 Alzheimer's cases.  No spirochetes have been
found in control patients.  Using a monoclonal antibody against Bb a
positive immunoreaction was seen in senile plaques and in neurons
was observer in the brain of a patient with concurrent Alzheimer's
disease and Lyme disease.  Individual spirochetes were observed.
The observations seem to reinforce the author's hypothesis that
Alzheimer's disease may correspond to the tertiary stage of
neurospirochetosis. Exactly which spirochetes are involved is yet to
be determined.


[ Comment - This information needless to say has met with some
 skepticism in both the Alzheimer's community and the Lyme community.
 The information as presented is compelling.  We should keep an open
 mind until more research is completed.  Alzheimer's disease may
 have multiple causes - could spirochetes be involved?  I include
 the following three references for anyone interested:
 * Miklossy J.  Alzheimer's disease - A spirochetosis?  Neuroreport
   4:841-848, 1993
 * Miklossy J. Kasas S. Janzer RC. Ardizzoni F. Van der Loss H.  
   Further ultrastructural evidence that spirochetes may play a role
   in the etiology of Alzheimer's disease.  Neuroreport 5:1201-1204.
   1994
 * Miklossy J. Gern L. Darekar P. Janzer RC. Van der Loss H. Senile
   Plaques, Neurofibrillary Tangles, and Neuropil Threads Contain
   DNA? Journal of spirochetal and Tick-Borne Diseases 2:9-13.1995 ]


14. Borrelia burgdorferi surface DNA represents a possible target for
a new category of antimicrobial agents - C. Garon, Ph.D.


Report of work being done to identify agents that might be used to
interrupt DNA in Bb and thus find alternatives to antibiotics to
eradicate Bb from the system.  With the exception of trioxale (not a
clinically useful drug) crosslinking, Bb seemed relatively
insensitive to known eukaryotic and prokaryotic DNA replication
inhibitors.  Cis-platinum didn't appear to work.


NEW THERAPEUTIC APPROACHES

15. Cellular infection of human fibroblasts, Langerhans cells and
leukocytes by isolation of Borrelia with emphasis to antibiotic and
antibody treatment - D. Hulinska, Ph.D.


This presentation demonstrated that Bb enters fibroblasts.  Langerhans
cells and leukocytes and in these locations can be protected from the
effect of antibiotics and antibodies.


16. Evidence of the intracellular borreliae localization - S.
Donta, M.D.


That Bb persists after initial infection is well established.  Bb can
rarely be found following initial infection and dissemination.
Despite treatment for months and even years Bb can persist and be
detected by PCR and/or culture in blood, spinal fluid and urine.
Viruses in the latent state can not be found by DNA testing.  Could
the same be true for Bb?  Mechanism of persistence is yet to be
definitively worked out.  Bb has a strong tropism to neural tissue;
brain, spinal cord and peripheral nerves.  Neural tissue invasion
alone can produce all the symptoms of Lyme disease according to Dr.
Donta.  Many examples (not all are enumerated here) of recurrent
disease or persistent infection were enumerated including viruses
(herpes, hepatitis B and C), parasites (malaria, leishmania,
toxoplama), fungi (cryptococcus, pneumocystus) and bacteria
(chlamydia, legionella, M. tuberculosis, T. pallidum, salmonella,
staphylococcus).  It is known that some of these persist inside
cells.  For others the location of persistence is unknown (T.

pallidum).  Tissue culture models of intracellular infection by Bb
have been described and in these models ceftriaxone was* ineffective*
in eliminating Bb from the cultures.  Dr. Donta theorized that
recurrent disease and persistence of Bb can be explained by the
intracellular localization of Bb.  He stated he knows of no other
plausible explanation for the persistence of any organism other than
in an intracellular location.  There are many good examples of
intracellularly localizing persistent organisms but no examples of
extracellular persistence are known.  Organisms can persist in
endosomes and endolysosomes within cells.  In this location they can
remain protected from the action of most antibiotics and antibodies.
He suggests that treatment of chronic Lyme disease needs antibiotics
that enter the cells.  Macrolide antibiotics enter cells but have
been less effective than expected.  He suggests it's because
macrolides do not work well in an acid environment, such as that in
endolysomal-like vesicles, that by using the lysosomotrophic agent

hydroxychlorlquine to increase the Ph of the endolysome along with the
administration of macrolide antibiotics the efficacy of the macrolide
antibiotics (clarithromycin, azithromycin, erythromycin) would be
increased.  Doxycycline and tetracycline also enter the cell so using
hydroxychloquine along with them may also improve treatment outcomes.
He also stated that amantadine 100mg three times daily has been
helpful in some Lyme patients.


[ Comment - Neurotropism of Bb according to Dr. Donta can account for
 all the symptoms of LD.  When you think about this it makes sense.
 Every organ and system in the body is dependent on the nervous
 system.  Certainly the obvious neurologic symptoms are real.
 But consider the pain syndromes that do not appear to be especially
 responsive to the usual analgesics - this is typical of neurogenic
 pain.  There are also reported effects of Bb on the endocrine
 system (stated by Dr. B. and others) - which may be explained by
 Bb's effects on the neuroendocrine system.  It stands to reason
 that if the nerve supply to any part or organ is affected by Bb
 symptoms referable to this organ or system may be expressed. ]



DIAGNOSTIC ADVANCEMENTS

17. Use of recombinant chimeric proteins for the diagnosis of Lyme
Disease - B. Luft, M.D.


Work to develop a Lyme test which is accurate and economical using
recombinant antigens was described.  The information presented showed
it to be feasible to develop such a test based on a recombinant
multivalent antigen.  Peptides from OspA, OspB, OspC, p41 and p93 are
being studied.



=====*=====


II.   ABOUT THE LYMENET NEWSLETTER
-----------------------------------
For the most current information on LymeNet subscriptions,
contributions, and other sources of information on Lyme disease,
please request the LymeNet Resource Guide.  To obtain the Guide,
send a blank message to:      resource-guide@lymenet.org
-----------------------------------------------------------------------
The LymeNet Resource Guide is in Revision:  1.10  
-----------------------------------------------------------------------
LymeNet - The Internet Lyme Disease Information Source
-----------------------------------------------------------------------
Editor-in-Chief: Marc C. Gabriel <a229@Lehigh.EDU>
           FAX: 908-789-0028
Contributing Editors: Carl Brenner <brenner@ldeo.Columbia.EDU>
                     John Setel O'Donnell <jod@Equator.COM>
                     Frank Demarest <76116.2065@CompuServe.COM>
Advisors: Carol-Jane Stolow, Director <carol@lymenet.org>
         William S. Stolow, President <bill@lymenet.org>

         The Lyme Disease Network of New Jersey (908-390-5027)
-----------------------------------------------------------------------
WHEN COMMENTS ARE PRESENTED WITH AN ATTRIBUTION, THEY DO NOT
NECESSARILY REPRESENT THE OPINIONS/ANALYSES OF THE EDITORS.
-----------------------------------------------------------------------
THIS NEWSLETTER MAY BE REPRODUCED AND/OR POSTED ON BULLETIN BOARDS
FREELY AS LONG AS IT IS NOT MODIFIED OR ABRIDGED IN ANY WAY.
-----------------------------------------------------------------------
SEND ALL BUG REPORTS TO a229@Lehigh.EDU
-----------------------------------------------------------------------


Home | Flash Discussion | Support Groups | On-Line Library
Legal Resources | Medical Abstracts | Newsletter | Books
Pictures | Site Search | Links | Help/Questions
About LymeNet


© 1994-1999 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to the Terms of Use.